Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Corcept Therapeutics Incorporated - Common Stock
(NQ:
CORT
)
75.54
-0.21 (-0.28%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Corcept Therapeutics Incorporated - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
July 17, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
June 27, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Analyst Expectations for Corcept Therapeutics's Future
↗
May 26, 2023
Via
Benzinga
Corcept Therapeutics's Return On Capital Employed Overview
↗
May 10, 2023
Via
Benzinga
Analyst Ratings for Corcept Therapeutics
↗
April 04, 2023
Via
Benzinga
Analyst Expectations for Corcept Therapeutics's Future
↗
March 08, 2023
Via
Benzinga
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
May 03, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 26, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2023
↗
April 11, 2023
Via
Benzinga
Corcept Therapeutics Announces Final Results of Tender Offer
April 05, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Short Volatility Alert: Corcept Therapeutics
↗
April 05, 2023
On Tuesday, shares of Corcept Therapeutics (NASDAQ: CORT) experienced volatile short activity. After the activity, the stock price went up +1.66% to $22.02. The overall sentiment for CORT has been...
Via
Benzinga
Corcept Therapeutics Announces Preliminary Results of Tender Offer
April 03, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Initiates CATALYST Clinical Trial
March 28, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
↗
April 04, 2023
Via
Benzinga
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock
March 06, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update
February 28, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
↗
February 15, 2023
Via
Benzinga
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
February 14, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
February 13, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT
December 28, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
December 16, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
December 15, 2022
From
The Schall Law Firm
Via
Business Wire
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
↗
December 15, 2022
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Our 7 Top Biotech Stock Picks for 2023
↗
December 09, 2022
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.
Via
InvestorPlace
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
December 08, 2022
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Provides Miricorilant Clinical Development Update
December 08, 2022
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
November 03, 2022
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics's Earnings: A Preview
↗
November 02, 2022
Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 27, 2022
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
These 3 Stocks Are Winning the Bear Market -- Here's How
↗
October 21, 2022
Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.
Via
The Motley Fool
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today